TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07102381: A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Sponsor: Jazz Pharmaceuticals · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 125 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07102381 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07102381 Rescue Dossier →